New shot aims to tame genital herpes outbreaks
NCT ID NCT05298254
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 26 times
Summary
This study tested an experimental immunotherapy for herpes simplex virus (HSV) in 505 people. Part 1 looked at safety in healthy adults aged 18-40, and Part 2 tested two formulations in adults aged 18-60 with recurrent genital herpes. The goal was to see if the treatment could reduce outbreaks and improve the body's immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HERPES SIMPLEX are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Phoenix, Arizona, 85015, United States
-
GSK Investigational Site
Wichita, Kansas, 67207, United States
-
GSK Investigational Site
Kansas City, Missouri, 64114, United States
-
GSK Investigational Site
Rochester, New York, 14609, United States
-
GSK Investigational Site
Richmond, Virginia, 23219, United States
-
GSK Investigational Site
Seattle, Washington, 98105, United States
-
GSK Investigational Site
Darlinghurst, New South Wales, 2010, Australia
-
GSK Investigational Site
Sydney, New South Wales, 2010, Australia
-
GSK Investigational Site
Antwerp, 2000, Belgium
-
GSK Investigational Site
Brussels, 1000, Belgium
-
GSK Investigational Site
Edegem, 2650, Belgium
-
GSK Investigational Site
Ghent, 9000, Belgium
-
GSK Investigational Site
Montreal, Quebec, H2L 4E9, Canada
-
GSK Investigational Site
Tartu, 50106, Estonia
-
GSK Investigational Site
Berlin, 10117, Germany
-
GSK Investigational Site
Berlin, 10439, Germany
-
GSK Investigational Site
Bochum, 44787, Germany
-
GSK Investigational Site
Cologne, 50674, Germany
-
GSK Investigational Site
Frankfurt, 60596, Germany
-
GSK Investigational Site
Hamburg, 20146, Germany
-
GSK Investigational Site
Barcelona, 08001, Spain
-
GSK Investigational Site
Barcelona, 08015, Spain
-
GSK Investigational Site
Madrid, 28010, Spain
-
GSK Investigational Site
Madrid, 28040, Spain
-
GSK Investigational Site
Madrid, 28222, Spain
-
GSK Investigational Site
Marbella, 29600, Spain
-
GSK Investigational Site
Brighton, BN2 1ES, United Kingdom
-
GSK Investigational Site
Liverpool, L7 8XP, United Kingdom
-
GSK Investigational Site
London, WC1E 6JB, United Kingdom
-
GSK Investigational Site
Southampton, SO14 0YG, United Kingdom
Conditions
Explore the condition pages connected to this study.